Pharmacokinetic/pharmacodynamic target attainment of eravacycline in a liver transplant recipient with refractory VRE faecium infection | Synapse
May 31, 2026Open Access
Pharmacokinetic/pharmacodynamic target attainment of eravacycline in a liver transplant recipient with refractory VRE faecium infection
Key Points
This research aims to evaluate the pharmacokinetic and pharmacodynamic properties of eravacycline in a liver transplant recipient with a resistant infection.
Analyzed pharmacokinetic and pharmacodynamic data for eravacycline in a liver transplant patient.
Monitored target attainment levels for effective infection management.
Achieved effective pharmacokinetic/pharmacodynamic target levels for treating VRE faecium infection.